The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Targeted gene delivery of BMPR2 attenuates pulmonary hypertension
Open accessAbstract
Pulmonary arterial hypertension (PAH) remains a fatal disease despite modern pharmacotherapy. Mutations in the gene for bone morphogenetic protein receptor type II ( BMPR2 ) lead to reduced BMPR2 expression, which is causally linked to PAH. BMPR2 is predominantly expressed on pulmonary endothelium and has complex interactions with transforming growth factor (TGF)-β signalling mechanisms. Our objectives were to assess the effect on PAH of upregulating BMPR2 by targeted adenoviral BMPR2 gene delivery to the pulmonary vascular endothelium. We used two established rat models of PAH: chronic hypoxia and monocrotaline (MCT). In both hypertensive models, those receiving BMPR2 had less right ventricular hypertrophy, less pulmonary vascular resistance, improved cardiac function and reduced vascular remodelling. In the MCT model, there was an increase in TGF-β, which was prevented by BMPR2 treatment. In vitro , TGF-β1-induced endothelial–mesenchymal transition (EndMT) in human pulmonary microvascular endothelial cells, which was associated with reduced BMPR2 expression. EndMT was partially ameliorated by stimulating BMPR2 signalling with appropriate ligands even in the ongoing presence of TGF-β1. Collectively, these results indicate therapeutic potential for upregulation of the BMPR2 axis in PAH, which may be, in part, mediated by countering the remodelling effects of TGF-β.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., Frost, A., Barst, R. J., Badesch, D. B., Elliott, C. G., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.898122 · Cited by 1,547
Cited by
Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension
Ranchoux, B., Antigny, F., Rucker-Martin, C., Hautefort, A., Péchoux, C., Bogaard, H. J., Dorfmüller, P., Remy, S., Lecerf, F., Planté, S., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.008750 · Cited by 576
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension
Long, L., Ormiston, M. L., Yang, X., Southwood, M., Gräf, S., Machado, R. D., Mueller, M., Kinzel, B., Yung, L. M., Wilkinson, J. M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3877 · Cited by 513
FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension
Spiekerkoetter, E., Tian, X., Cai, J., Hopper, R. K., Sudheendra, D., Li, C. G., El-Bizri, N., Sawada, H., Haghighat, R., Chan, R., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65592 · Cited by 449
Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension
Humbert, M., Lau, E. M. T., Montani, D., Jaïs, X., Sitbon, O., & Simonneau, G. (2014) · Circulation · doi:10.1161/circulationaha.114.006974 · Cited by 342
Cho, J. G., Lee, A., Chang, W., Lee, M.-S., & Kim, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00294 · Cited by 284
Metadata
- Authors
- Reynolds, A. M., Holmes, M. D., Danilov, S. M., & Reynolds, P. N.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2011-07-07
- Volume
- 39
- Issue
- 2
- Pages
- 329-343
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2035782659
- Cited by
- 186
- References
- 1
- FWCI
- 8.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. https://app.cochat.ai/papers/10.1183/09031936.00187310
- The paper
- Reynolds, A. M., Holmes, M. D., Danilov, S. M., & Reynolds, P. N. (2012). Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. European Respiratory Journal. https://doi.org/10.1183/09031936.00187310
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.